Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
18.07
+0.19 (1.06%)
At close: Mar 9, 2026, 4:00 PM EDT
18.07
0.00 (0.00%)
After-hours: Mar 9, 2026, 7:00 PM EDT
Takeda Pharmaceutical Revenue
Takeda Pharmaceutical had revenue of 1.19T JPY in the quarter ending December 31, 2025, with 4.16% growth. This brings the company's revenue in the last twelve months to 4.46T, down -2.50% year-over-year. In the fiscal year ending March 31, 2025, Takeda Pharmaceutical had annual revenue of 4.58T with 7.45% growth.
Revenue (ttm)
4,464.58B JPY
Revenue Growth
-2.50%
P/S Ratio
1.97
Revenue / Employee
94,080,244 JPY
Employees
47,455
Market Cap
56.11B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 4,581.55B | 317.79B | 7.45% |
| Mar 31, 2024 | 4,263.76B | 236.28B | 5.87% |
| Mar 31, 2023 | 4,027.48B | 458.47B | 12.85% |
| Mar 31, 2022 | 3,569.01B | 371.19B | 11.61% |
| Mar 31, 2021 | 3,197.81B | -93.38B | -2.84% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Teva Pharmaceutical Industries | 17.26B |
| Haleon | 14.85B |
| Viatris | 14.30B |
| Zoetis | 9.47B |
| Elanco Animal Health | 4.72B |
| Dr. Reddy's Laboratories | 3.85B |
| United Therapeutics | 3.18B |
| Neurocrine Biosciences | 2.86B |
TAK News
- 5 days ago - Takeda Pharmaceutical Company Limited (TAK) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 5 days ago - Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results - Benzinga
- 7 days ago - Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera - Business Wire
- 18 days ago - Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis - Business Wire
- 27 days ago - Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market - Benzinga
- 27 days ago - U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda's Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1 - Business Wire
- 4 weeks ago - Takeda Taps AI Startup Iambic In $1.7 Billion+ Deal To Speed Up Drug Discovery - Benzinga
- 4 weeks ago - Takeda Taps AI Startup Iambic In $1.7 Billion+ Deal To Speed Up Drug Discovery - Benzinga